GlassScriptPhysician profile
Jerry Steven Johnson
NPI 1053392217
$3,304.04
in general payments reported to CMS, 2019-2025
31 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,678 · 2020: $553 · 2021: $181 · 2022: $345 · 2023: $79.73 · 2024: $175 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $963.05 | 2019 | |
| Novocure INC. | $382.32 | 2019-2024 | Optune |
| Boston Scientific Corporation | $250.66 | 2020 | |
| Varian Medical Systems, INC. | $144.06 | 2019 | |
| Janssen Biotech, INC. | $135.60 | 2020-2022 | |
| Palette Life Sciences, INC. | $134.26 | 2022 | |
| Isoray, INC | $124.99 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $121.08 | 2022-2024 | Monoferric |
| Amgen INC. | $108.28 | 2019-2022 | |
| Elekta, INC. | $102.40 | 2019-2025 | Elekta Unity |
| Janssen Pharmaceuticals, INC | $100.00 | 2019 | |
| Gilead Sciences, INC. | $80.77 | 2019 | |
| Siemens Medical Solutions USA, INC. | $74.33 | 2024-2025 | Truebeam |
| Veran Medical Technologies, INC. | $69.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.95 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66.21 | 2025 | Enhertu |
| Merck Sharp & Dohme LLC | $53.96 | 2022-2025 | Keytruda |
| Seagen INC. | $47.82 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $35.83 | 2022-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $35.61 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $25.73 | 2021 | |
| Myriad Genetic Laboratories, INC. | $23.29 | 2025 | Prolaris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.47 | 2021 | |
| Amag Pharmaceuticals, INC. | $20.82 | 2021 | |
| Biom'Up Sa | $20.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2025 | Fruzaqla |
| Lilly USA, LLC | $18.60 | 2025 | Jaypirca, Verzenio |
| Eisai INC. | $15.85 | 2022 | |
| Abbvie INC. | $14.92 | 2024 | |
| Medtronic, INC. | $13.91 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.